Brought to you by 
Wellcome licenses Vertex HIV protease inhibitors
Jan 1994
Executive Summary
Wellcome has licensed US & European rights to Vertex's HIV protease inhibitors, the most advanced of which are currently in preclinical studies. The transaction is worth a potential $42 million to Vertex in initial fees and research payments.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R+D and Marketing-Licensing
- Includes Equity
- Includes Royalty or Profit Split Information
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Wellcome licenses Vertex HIV protease inhibitors
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice